At a glance
ClinicalIndex Comparison RecordN/ACompleted· 323 enrolled
Drug / intervention
Anti-VEGFdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema
In Brief
An observational study evaluating Anti-VEGF for Retinal Vein Occlusion and Macular Edema. Completed, enrolled 323 participants across 1 site.
Detailed Summary
This retrospective data review study will evaluate anti-VEGF injections for retinal vein occlusion (RVO) or diabetic macular edema (DME).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRetinal Vein Occlusion, Macular Edema
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartAug 2013
First PostedAug 2013
Primary CompletionSep 2014
TodayJul 2026
First PostedAug 7, 2013
Enrollment StartAug 2, 2013
Primary CompletionSep 4, 2014
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 12.9 years ago
Interventions
Anti-VEGFdrug
Patients with retinal vein occlusion or diabetic macular edema receiving anti-VEGF injection(s) in accordance with standard of care practices. This is a retrospective chart review study.